WO1999011772A1 - Transgenic animals for the study of biological, physical and chemical toxic agents - Google Patents

Transgenic animals for the study of biological, physical and chemical toxic agents Download PDF

Info

Publication number
WO1999011772A1
WO1999011772A1 PCT/IT1998/000231 IT9800231W WO9911772A1 WO 1999011772 A1 WO1999011772 A1 WO 1999011772A1 IT 9800231 W IT9800231 W IT 9800231W WO 9911772 A1 WO9911772 A1 WO 9911772A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
toxicity
gene
study
tran
Prior art date
Application number
PCT/IT1998/000231
Other languages
French (fr)
Inventor
Maria Grazia Sacco
Luigi Zecca
Peter Bromley
Libero A. Clerici
Paolo Vezzoni
Romeo Roncucci
Original Assignee
Consiglio Nazionale Delle Ricerche
Gene Control S.A.
EUROPEAN COMMUNITY, represented by THE COMMISSION OF THE EUROPEAN COMMUNITIES ;
Roncucci, Sylvie
CASTAGNOLI, Maria Novella, legal representative of RONCUCCI, Rachele (Hieress of RONUCCI, Romeo (deceased))
CASTAGNOLI, Maria, Novella_legal representative of RONCUCCI, Régine (Hieress of RONCUCCI, Romeo (deceased))
DELACHET, Anne, Georgette, Christiane legal representative of RONCUCCI, Roxanne (Hieress of RONCUCCI, Romeo (deceased))
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Delle Ricerche, Gene Control S.A., EUROPEAN COMMUNITY, represented by THE COMMISSION OF THE EUROPEAN COMMUNITIES ;, Roncucci, Sylvie, CASTAGNOLI, Maria Novella, legal representative of RONCUCCI, Rachele (Hieress of RONUCCI, Romeo (deceased)), CASTAGNOLI, Maria, Novella_legal representative of RONCUCCI, Régine (Hieress of RONCUCCI, Romeo (deceased)), DELACHET, Anne, Georgette, Christiane legal representative of RONCUCCI, Roxanne (Hieress of RONCUCCI, Romeo (deceased)) filed Critical Consiglio Nazionale Delle Ricerche
Priority to JP2000508783A priority Critical patent/JP2001514848A/en
Priority to CA002302220A priority patent/CA2302220A1/en
Priority to AU86469/98A priority patent/AU8646998A/en
Priority to EP98937782A priority patent/EP1029037A1/en
Publication of WO1999011772A1 publication Critical patent/WO1999011772A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Definitions

  • the present invention provides transgemc animals for the study of biological, physical and chemical toxic agents .
  • toxicity tests can be carried out both in vivo and m vitro.
  • EP 0 169 672 Bl describes transgemc animals bearing oncogene ⁇ like c-myc, suitable for the study of tumors associated to the expression of such oncogenes, or bearing the human growth hormone gene fused to a metallothionein promoter, whereby, said promoter being an inducible promoter, it is possible to study the effect of the expression, upon induction, of the associated gene on the whole organism (Palmiter et al. (1983) Science 222, 809).
  • WO 91/15579 describes a method for studying mutage- ne ⁇ is in transgenic animals bearing DNA sequences which can easily be extracted and analysed for mutations.
  • the present invention provides non-human transgenic animals useful for toxicity studies.
  • Such animals are characterised in that they have regulatory DNA sequences in some or all their cells, which are sensitive to biological, physical and chemical toxic agents, functionally linked to sequences of reporter genes, whereby the expression of the latter sequences is controlled or induced by said regulatory sequences .
  • the stress-promoter sequences like the heat shock protein (h ⁇ p) promoters, are preferred, but also cytochrome-promoters of the p450-superfa ily , as well as those promoters of other genes, like p53 gene, activated by biological, chemical or physical stress, can be cited.
  • the growth hormone gene which has been used in the experiments described below, is preferred, but also chlorarnphenicol acetyl tran ⁇ ferase (CAT), green fluorescence protein (GFP) and ⁇ -galactosida ⁇ e ( acZ) genes can be suitably employed.
  • CAT chlorarnphenicol acetyl tran ⁇ ferase
  • GFP green fluorescence protein
  • acZ ⁇ -galactosida ⁇ e
  • the transgenic animals of the invention can be used m a method for studying the toxicity induced by various agents.
  • any animal normally suitable for a toxicity test can be used the method of the invention.
  • non-human mammals particularly primates and rodents, are preferred.
  • mice in particular, are the most preferred.
  • Conventional ethod ⁇ can be u ⁇ ed for the production of transgemc animals, including, for example, the micromiection of recombmant DNA into embryonal cells or into pronuclei of one-cell stage embryos, the zygote , embryo cell, somatic cell or animal tis ⁇ ue infection with a virus, m particular with a retrovirus, according to what described, for example, in Hogan et al., Cold Spring Harbor Laboratory Press, NY, 1986; Pal iter et al., Ann. Rev. Genet., 20: 465-499; 1986; Capecchi,
  • the method for the m vivo assay of potential toxic compounds according to the present invention comprise ⁇ exposing the animal to a chemical or phy ⁇ ical agent for a time sufficient to induce the effect, and simply measuring the reporter gene expression.
  • the reporter gene encodes a protein secreted in the bloodstream, for instance, its hematic concentration, as well as other chemical-clinical parameters associated with the effect caused by the activation of the stress promoter, could be detected.
  • a preferred embodiment is the production of transgenic mice in which a construct has been inserted, which comprises a hsp promoter fused to growth hormone (GH) gene (transgene), said promoter being described
  • GH growth hormone
  • the injury caused by the toxic agent is determined as the increase of GH plasma concentration versus the control.
  • This model has resulted particularly efficient and sensitive, especially in relation with toxic metals, but it can suitably be used also for other classes of chemical toxic compounds, like endocrine di ⁇ ruptor ⁇ , as well as for other physical or chemical agents, like radiations and electromagnetic fields.
  • the ma advantages offered by the invention are: the possibility to diminish animal suffering, since only low amounts of the te ⁇ t ⁇ ub ⁇ tances are used, surely lower than the dosages which could induce animal suffering or death; the reduction of the number of animals used m toxicological tests; the provision of a model that is absolutely reliable for what concerns the metabolic modifications, which the toxic agents undergo in the organism, the interactions of toxic compounds with various organs and their final effects on cells, including the chronic effects.
  • This model is particularly useful for te ⁇ t reiterations and allows to monitor the agent's effect during long-lasting treatments using always the ⁇ ame animal, thu ⁇ eliminating the variability of the individual re ⁇ pon ⁇ e.
  • the second aspect of the invention concerns the possibility to obtain primary cultures of cells from different ti ⁇ sue ⁇ of the transgenic animal, in which a recombmant DNA construct is integrated as described above, whereby a cell- or ti ⁇ ue- ⁇ pecific toxicity study can be carried out and the intracellular biochemical effects connected to toxicity can be evaluated under controlled conditions and in more detail during different stages of animal growth.
  • the in vitro a ⁇ say compri ⁇ es preparing primary cultures in conditions variable depending on the cell type, exposing said cultures to the toxic agent and monitoring the activation of the stress promoter through detection of the protein encoded by the reporter gene.
  • an embodiment of the second aspect of the invention consists for example in preparing primary cultures of fibroblasts, kidney, lung or bone marrow cells, hepatocytes or other, in their ⁇ imultaneou ⁇ or ⁇ eparate treatment with one or more toxic agent ⁇ , and in the determination of GH secretion in the medium. If, using the above assay, a tis ⁇ ue or a cell-type resulted sensitive to the toxic agent, a deeper biochemical analysis could be made m order to find which cellular pathways are particularly involved m the toxicity .
  • the invention provides a method to carry out vitro toxicity tests on primary cultures of somatic cells derived from a transgemc animal .
  • Fig. Panel A Southern blot analysis of transgenic heterozygous (lanes 1-4) and ho ozygous mice (lanes 5-7) and a non-transgemc control mouse (lane 8).
  • Panel B RT-PCR with hGH specific primers of heat- shock activated liver cells from transgenic mice.
  • Samples RNA from cultured hepatocyte ⁇ before (lane 1) and 30 mm after (lane 2) heat ⁇ hock in vitro; RNA from livers before (lane 3) and 30, 60, 90, minutes after heat ⁇ hock (lanes 4-6). + and - represent the negative and positive controls re ⁇ pectively .
  • Lanes 7 to 10 are the amplifications on non-retrotranscribed liver RNAs performed on the same samples as in lanes 3 to 6.
  • Ml marker V
  • M2 1 kb ladder.
  • Panel C RT-PCR with HPRT specific primers performed on RNAs from the sample ⁇ 1 to 6 a ⁇ m panel B.
  • Fig. 2 Plasma levels of hGH (pg/ml) measured at different times in transgenic mice after thermal ⁇ tre ⁇ .
  • Values represent the mean ⁇ SE; the number of mice tested for each time period is indicated by the number above each bar.
  • Fig. 3 Mean hGH plasma levels (pg/ml) ⁇ SE observed transgenic mice injected l.p with PBS and with various inorganic toxic compounds at the indicated doses. Besides controls, are indicated: Rb : rubidium chloride; Hg : methylmercurium chloride; Cu copper sulphate; Cd : cadmium chloride; As- sodium ar ⁇ emte (2 do ⁇ es) (below each bar is given the number of tested mice). The levels of significance are: p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.005
  • Fig. 4 Mean ⁇ SE of plasma hGH level ⁇ observed in transgenic mice subjected to two consecutive treatments, according to the following schema:
  • Transgenic mice were produced according to standard techniques (Hogan et al., "Manipulating the mouse embryo: a laboratory manual", Cold Spring Harbor Laboratory Pres ⁇ , Cold Spring Harbor, N.Y., 1986), by microinjectmg 1-cell ⁇ tage embryo pronuclei with a 1.4 kb EcoRI DNA fragment from pl7hGH con ⁇ truct (described m Dreano et al., Biotechnology 6:953, 1988 and Gene 49:1-8, 1986), containing the human growth hormone cDNA a ⁇ reporter gene, fused to the control region of the human H ⁇ p70 promoter.
  • mice were screened by Southern blot and/or PCR performed on tail DNA according to standard techniques. PCR was performed with the following primers: hGH : GTGCAGTTCCTCAGGAGTGT; hGHR : CGAACTTGCTGTAGGTCTGC .
  • the amplification product was 171 bp long.
  • Amplification conditions 35 cycles were: 94°C for 20 sec, 58°C for 30 sec and 72°C for 20 ⁇ ec .
  • Heterozygous males and females were crossed and the homozygous progeny was identified by Southern blot, based on the intensity of the transgenic bands; their homozygo ⁇ ity wa ⁇ confirmed by checking the offspring when the homozygous male was mated to a non-transgenic partner.
  • the mice u ⁇ ed for the in vitro and in vivo experiment ⁇ were always derived from a homozygou ⁇ male bred with a non-tran ⁇ genic CD-I female.
  • RNA wa ⁇ extracted from different ti ⁇ ue ⁇ liver, ⁇ pleen, lung, kidney, blood
  • ti ⁇ ue ⁇ liver, ⁇ pleen, lung, kidney, blood
  • Southern and Northern blot were performed according to standard technique ⁇ .
  • mice were analysed with Northern blot and with RT-PCR.
  • transgenic mice obtained according to example 1 and four non-transgenic control mice were subjected to in vivo heat shock at 44"C for 30 in.
  • EXAMPLE 3 a) Inducibility of the hsp70/hGH tran ⁇ gene expre ⁇ sion in vivo by ⁇ odiu ar ⁇ enite and methylmercurium chloride.
  • Male tran ⁇ genic mice obtained as described in example 1 were weighed, anesthetized with ether and injected intraperitoneally (i.p.) with NaA ⁇ O ⁇ di ⁇ olved in PBS, at a final dose of 2.5 or 5 mg/kg, or with 3.5 mg/kg CH ⁇ HgCl dis ⁇ olved in PBS.
  • Control tran ⁇ genic mice were injected with the same volume of PBS (about 200 ⁇ l/mouse ) .
  • mice with As 5 mice with As, 3 mice with Cd, 2 mice with Rb, 3 mice with Cu .
  • the former three group ⁇ of mice were re-moculated with A ⁇ , the latter with Cu.
  • Blood samples were taken before and 3-5 hours after injection, I e . at the time ⁇ of highe ⁇ t re ⁇ pon ⁇ e.
  • mice showed a response comparable to that observed in groups of mice treated as m example 3
  • EFIS embryonic fibroblasts
  • cells were treated by substituting the culture medium with fresh pre-warmed serum-free medium containing the toxic compounds at the chosen final dilutions. Cells were exposed to the toxic compound for either 5 or 24 hours and then the medium wa ⁇ replaced with fresh control medium for an additional 24 hours. At the end of the treatment, culture media were collected and as ⁇ ayed for hGH secretion by enzyme immunoassay.
  • Kidney and lung cell ⁇ were recovered as de ⁇ cribed by Campbell, J. A. et al. ("Si ⁇ ter cromatid exchange analysis of mice following in vitro exposure to vinyl carbonate", In vitro Cell. Dev . Biol. 22: 443:448,
  • kidneys were removed from the same animals subjected to liver perfu ⁇ ion, wa ⁇ hed 3 time ⁇ in PBS additioned with antibiotic ⁇ and minced in 0.5 mm piece ⁇ with a ⁇ terile ⁇ calpel. After 1 hour of incubation in tryp ⁇ in/collagena ⁇ e (lOOU/ml) ⁇ olution, the su ⁇ pen ⁇ ion wa ⁇ centrifuged twice for 5 min. at 50xg, plated in 100 mm Falcon dishe ⁇ and cultured in McCoy ' ⁇ medium with 20% FCS, 2mM Glutamine and Pen/ ⁇ trep.
  • bone marrow cells were flushexd from the cavity of femurs and tibias with a ⁇ yringe containing the culture medium.
  • Cell ⁇ were plated in 12 well plate ⁇ with McCoy' ⁇ medium with 20% FCS, 2mM Glutamine and antibiotic ⁇ , and left to grow until the ⁇ tromal cell ⁇ reached confluence.
  • hGH levels in untreated cells medium (controls) were not measurable after 5-24-hour incubation .
  • hGH levels in untreated cells medium (controls) were not measurable after 24-hour incubation.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides non-human transgenic animals bearing regulatory DNA sequences in some or all their cells, which are sensitive to biological, physical and chemical toxic agents. Such sequences are linked to sequences of reporter genes useful for toxicological studies.

Description

TRANSGENIC ANIMALS FOR THE STUDY OF BIOLOGICAL, PHYSICAL AND CHEMICAL TOXIC AGENTS
The present invention provides transgemc animals for the study of biological, physical and chemical toxic agents .
At present, toxicity tests can be carried out both in vivo and m vitro.
The industrials, the public opinion and the scientific community are strongly interested m the abolition of toxicity tests made on animals and therefore in their replacement with in vitro tests. This target, however, is quite unrealistic at the moment, since no in vitro tests which can replace in vivo tests are available, either now or m the near future .
It is well known, in fact, that the substances under in vivo investigation often undergo metabolic modifications, which might significantly alter their toxicity profile, to an extent which would be unpredictable m in vitro tests.
On the other hand, m vivo studies always involve animal suffering and sacrifice.
However, it is possible to conceive genetically- engineered animal models which may simplify the determination of the toxicity of various agents and reduce the number of animals involved. Recently, the use of transgemc animals as models for pharmacological studies has been proposed.
For example, EP 0 169 672 Bl describes transgemc animals bearing oncogeneε like c-myc, suitable for the study of tumors associated to the expression of such oncogenes, or bearing the human growth hormone gene fused to a metallothionein promoter, whereby, said promoter being an inducible promoter, it is possible to study the effect of the expression, upon induction, of the associated gene on the whole organism (Palmiter et al. (1983) Science 222, 809).
WO 91/15579 describes a method for studying mutage- neεis in transgenic animals bearing DNA sequences which can easily be extracted and analysed for mutations.
The present invention provides non-human transgenic animals useful for toxicity studies.
Such animals are characterised in that they have regulatory DNA sequences in some or all their cells, which are sensitive to biological, physical and chemical toxic agents, functionally linked to sequences of reporter genes, whereby the expression of the latter sequences is controlled or induced by said regulatory sequences . Among the regulatory sequences, the stress-promoter sequences, like the heat shock protein (hεp) promoters, are preferred, but also cytochrome-promoters of the p450-superfa ily , as well as those promoters of other genes, like p53 gene, activated by biological, chemical or physical stress, can be cited.
Among suitable reporter genes, the growth hormone gene, which has been used in the experiments described below, is preferred, but also chlorarnphenicol acetyl tranεferase (CAT), green fluorescence protein (GFP) and β-galactosidaεe ( acZ) genes can be suitably employed.
The transgenic animals of the invention can be used m a method for studying the toxicity induced by various agents.
In theory, any animal normally suitable for a toxicity test can be used the method of the invention In practice, non-human mammals, particularly primates and rodents, are preferred.
Mice, in particular, are the most preferred. Conventional ethodε can be uεed for the production of transgemc animals, including, for example, the micromiection of recombmant DNA into embryonal cells or into pronuclei of one-cell stage embryos, the zygote , embryo cell, somatic cell or animal tisεue infection with a virus, m particular with a retrovirus, according to what described, for example, in Hogan et al., Cold Spring Harbor Laboratory Press, NY, 1986; Pal iter et al., Ann. Rev. Genet., 20: 465-499; 1986; Capecchi,
Science, 244: 288-292, 1989.
The method for the m vivo assay of potential toxic compounds according to the present invention, compriseε exposing the animal to a chemical or phyεical agent for a time sufficient to induce the effect, and simply measuring the reporter gene expression. When the reporter gene encodes a protein secreted in the bloodstream, for instance, its hematic concentration, as well as other chemical-clinical parameters associated with the effect caused by the activation of the stress promoter, could be detected.
According to the first aspect of the invention, a preferred embodiment is the production of transgenic mice in which a construct has been inserted, which comprises a hsp promoter fused to growth hormone (GH) gene (transgene), said promoter being described
Dreano et al. (Biotechnology u6:953, 1988 and Gene 49:1-
8, 1986) and in Fishbach et al . (Cell Biol . Toxicol .
9:177-188, 1993). The latter publication reports that the exposure to toxic metals of a stable fibroblast line, engineered with a construct containing the growth hormone gene under the control of hsp promoter, causes the secretion of the reporter gene in the medium.
According to the preferred embodiment of the invention, the injury caused by the toxic agent is determined as the increase of GH plasma concentration versus the control.
This model has resulted particularly efficient and sensitive, especially in relation with toxic metals, but it can suitably be used also for other classes of chemical toxic compounds, like endocrine diεruptorε, as well as for other physical or chemical agents, like radiations and electromagnetic fields.
The ma advantages offered by the invention are: the possibility to diminish animal suffering, since only low amounts of the teεt εubεtances are used, surely lower than the dosages which could induce animal suffering or death; the reduction of the number of animals used m toxicological tests; the provision of a model that is absolutely reliable for what concerns the metabolic modifications, which the toxic agents undergo in the organism, the interactions of toxic compounds with various organs and their final effects on cells, including the chronic effects. This model is particularly useful for teεt reiterations and allows to monitor the agent's effect during long-lasting treatments using always the εame animal, thuε eliminating the variability of the individual reεponεe.
Further, εeveral compounds can be studied using the same animal. Finally, such transgenic models can be used also for in vivo studies of toxicity kinetics of toxic compounds .
The second aspect of the invention concerns the possibility to obtain primary cultures of cells from different tiεsueε of the transgenic animal, in which a recombmant DNA construct is integrated as described above, whereby a cell- or tiεεue-εpecific toxicity study can be carried out and the intracellular biochemical effects connected to toxicity can be evaluated under controlled conditions and in more detail during different stages of animal growth.
In this case, the in vitro aεsay compriεes preparing primary cultures in conditions variable depending on the cell type, exposing said cultures to the toxic agent and monitoring the activation of the stress promoter through detection of the protein encoded by the reporter gene.
Referring to the above described transgenic mice bearing the hsp/GH construct, an embodiment of the second aspect of the invention consists for example in preparing primary cultures of fibroblasts, kidney, lung or bone marrow cells, hepatocytes or other, in their εimultaneouε or εeparate treatment with one or more toxic agentε, and in the determination of GH secretion in the medium. If, using the above assay, a tisεue or a cell-type resulted sensitive to the toxic agent, a deeper biochemical analysis could be made m order to find which cellular pathways are particularly involved m the toxicity .
Thuε, according to a further aspect, the invention provides a method to carry out vitro toxicity tests on primary cultures of somatic cells derived from a transgemc animal .
BRIEF DECRIPTION OF THE FIGURES
Fig 1. Panel A: Southern blot analysis of transgenic heterozygous (lanes 1-4) and ho ozygous mice (lanes 5-7) and a non-transgemc control mouse (lane 8).
Panel B: RT-PCR with hGH specific primers of heat- shock activated liver cells from transgenic mice. Samples: RNA from cultured hepatocyteε before (lane 1) and 30 mm after (lane 2) heat εhock in vitro; RNA from livers before (lane 3) and 30, 60, 90, minutes after heat εhock (lanes 4-6). + and - represent the negative and positive controls reεpectively . Lanes 7 to 10 are the amplifications on non-retrotranscribed liver RNAs performed on the same samples as in lanes 3 to 6. Ml: marker V, M2: 1 kb ladder.
Panel C: RT-PCR with HPRT specific primers performed on RNAs from the sampleε 1 to 6 aε m panel B.
Fig. 2: Plasma levels of hGH (pg/ml) measured at different times in transgenic mice after thermal εtreεε.
Values represent the mean ± SE; the number of mice tested for each time period is indicated by the number above each bar.
Fig. 3: Mean hGH plasma levels (pg/ml) ± SE observed transgenic mice injected l.p with PBS and with various inorganic toxic compounds at the indicated doses. Besides controls, are indicated: Rb : rubidium chloride; Hg : methylmercurium chloride; Cu copper sulphate; Cd : cadmium chloride; As- sodium arεemte (2 doεes) (below each bar is given the number of tested mice). The levels of significance are: p<0.05; **p<0.01; ***p<0.005
Fig. 4: Mean ± SE of plasma hGH levelε observed in transgenic mice subjected to two consecutive treatments, according to the following schema:
Group First Second Time treatment treatment Interval
(Tχ) (T2) (τ1-τ2)
As^ As Aε 10 days
Aε2 Cd As 2 months
Aε3 Rb As 2 months
Cu Cu Cu 2 months
Control untretated untreated
The following examples better llluεtrate the invention:
EXAMPLE 1
Production and characterization of a transαemc mouse lineage
Transgenic mice were produced according to standard techniques (Hogan et al., "Manipulating the mouse embryo: a laboratory manual", Cold Spring Harbor Laboratory Presε, Cold Spring Harbor, N.Y., 1986), by microinjectmg 1-cell εtage embryo pronuclei with a 1.4 kb EcoRI DNA fragment from pl7hGH conεtruct (described m Dreano et al., Biotechnology 6:953, 1988 and Gene 49:1-8, 1986), containing the human growth hormone cDNA aε reporter gene, fused to the control region of the human Hεp70 promoter.
Mice were screened by Southern blot and/or PCR performed on tail DNA according to standard techniques. PCR was performed with the following primers: hGH : GTGCAGTTCCTCAGGAGTGT; hGHR : CGAACTTGCTGTAGGTCTGC .
The amplification product was 171 bp long. Amplification conditions (35 cycles) were: 94°C for 20 sec, 58°C for 30 sec and 72°C for 20 εec . Heterozygous males and females were crossed and the homozygous progeny was identified by Southern blot, based on the intensity of the transgenic bands; their homozygoεity waε confirmed by checking the offspring when the homozygous male was mated to a non-transgenic partner. The mice uεed for the in vitro and in vivo experimentε were always derived from a homozygouε male bred with a non-tranεgenic CD-I female.
Total RNA waε extracted from different tiεεueε (liver, εpleen, lung, kidney, blood) of tranεgenic and control mice, according to standard techniques ( Sambrook et al., "Molecular cloning: a laboratory manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Southern and Northern blot were performed according to standard techniqueε.
In order to evaluate the baεal value of non-induced expreεεion of the tranεgene, mice were analysed with Northern blot and with RT-PCR.
No expreεεion waε detected in lung, kidney, εpleen, liver and peripheral blood lymphocytes of non-treated animals or of animals not-exposed to heat shock. The hGH level in non-treated mice (control) waε generally under the test detection limits, and when it was determined, it never exceeded 10 pg/ml.
EXAMPLE 2 Tn vivo heat shock treatment.
Eight transgenic mice obtained according to example 1 and four non-transgenic control mice were subjected to in vivo heat shock at 44"C for 30 in. Six additional unexpoεed transgenic mice were teεted. Aliquots of blood were taken before and 1, 3, 5, 7, and 24 hours after the heat shock.
In transgenic mice (Fig. 2) a specific increase of plasma hGH was detected with a peak three hour after treatment . These resultε suggest that the integrated transgene doeε not affect in vivo the normal reεponsiveneεε of hsp promoter .
EXAMPLE 3 a) Inducibility of the hsp70/hGH tranεgene expreεsion in vivo by εodiu arεenite and methylmercurium chloride. Male tranεgenic mice obtained as described in example 1 were weighed, anesthetized with ether and injected intraperitoneally (i.p.) with NaAεO^ diεεolved in PBS, at a final dose of 2.5 or 5 mg/kg, or with 3.5 mg/kg CH^HgCl disεolved in PBS. Control tranεgenic mice were injected with the same volume of PBS (about 200 μl/mouse ) .
Blood εamples were recovered before injection and 1, 3, 5, 7 and 24 hours after treatment. hGH plasma levels at different times and doses are shown in Fig. 3. Both the teεted doεeε of NaAε02 gave a clear and statistically significant response
The responεe peaked after 3-5 hours and turned to the basal level 24 hours after injection CH HgCl gave hGH peaks after 5-7 hours and baseline hGH valueε 24 hours after injection. b) Following the same procedure aε deεcribed m a), hGH inducibility waε evaluated m mice treated with rubidium chloride (18.5 mg/kg, c), copper εulfate (9 mg/kg, d) and cadmium chloride (4.7 mg/kg, e).
Results are reported in Fig. 3. XAMPL 4
Inducibility of the hsp70/hGH tranεαene expression in vivo by repeated lmections of toxic compounds . Initially, 13 mice were treated aε follows:
5 mice with As, 3 mice with Cd, 2 mice with Rb, 3 mice with Cu . After a period of 10 dayε to 2 months, the former three groupε of mice were re-moculated with Aε , the latter with Cu. Blood samples were taken before and 3-5 hours after injection, I e . at the timeε of higheεt reεponεe.
As shown m Fig. 4, after the first administration of the compound, the mice showed a response comparable to that observed in groups of mice treated as m example 3
When retested after 10-60 dayε, a similar hGH increase was observed. EXAMPLE 5
Embryonic fibroblast primary cultures-in vitro toxicity tests.
Homozygous transgenic mice obtained aε described in example 1 were croεεed with CD-I femaleε After 14 days, embryonic fibroblasts (EMFIS) were recovered from the fetuεeε according to the technique deεcribed by
Robertson E.J., IRL Press, Oxford, 77-88, 1987. Cellε were cultured in DMEM supplemented with 10%
FCS and antibiotics (pen/strep), in an incubator
(C02:5%, 100% humidity). Culture medium waε replaced every second day with pre-warmed (37°C) fresh culture medium. The cells were expanded for two passages and then frozen at -80°C. For each experiment, cells were thawed, plated in 10 cm Petri dishes, left to grow and then re-seeded on 12 well plates until confluence.
To evaluate the toxic effect of the compounds, cells were treated by substituting the culture medium with fresh pre-warmed serum-free medium containing the toxic compounds at the chosen final dilutions. Cells were exposed to the toxic compound for either 5 or 24 hours and then the medium waε replaced with fresh control medium for an additional 24 hours. At the end of the treatment, culture media were collected and asεayed for hGH secretion by enzyme immunoassay.
Each treatment was performed in triplicate and the hGH determination waε repeated twice for each plate. The results are expresεed as pg of hGH/10^ cells. The sensitivity of this method waε approximately 2-4 pg/ml.
As shown m the table, calcium and rubidium, known for their lack of toxicity at the tested concentrations, do not provoke hGH release the medium.
On the contrary, a significant release is induced after 24 hours of chrome exposure, while copper gives a low reεponεe after 24 hourε at the higheεt concentrations. On the contrary, mercurium doeε not induce hGH release from fibroblasts at each tested concentration.
Finally, arsenic and cadmium, as expected, showed clearly toxic.
EXAMPLE 6
Primary hepatocvtes cultureε-in vitro toxicitv tests.
Tranεgenic male mice 8 weekε old were anesthetized and their livers were perfuεed aε deεcribed in Clerici et al., Mut. Res., 227:47-51, 1989, in order to collect hepatocytes. Hepatocyteε were then εeeded on 24 well plateε (2x10^ cellε/well) and cultured in William'ε E medium supplemented with antibiotics (pen/strep) and 10% FCS for 2 hours in order to allow them to attach to the bottom of the Petri disheε. The supernatant was then removed and the adherent cellε were treated with the compoundε diεsolved in the medium.
To evaluate the toxic effect of the compoundε, cells were treated by subεtituting the culture medium with fresh pre-warmed serum-free medium containing the toxic compounds at the chosen final dilutionε.
Aε εhown in the table, calcium and rubidium do not induce hGH releaεe by mature hepatocyteε. Chrome treatment induceε a high response after 24 hours, while copper treatment causes releaεe either after 5 or 24 hourε at each concentration.
Mercurium induces a response at concentrations higher than 5xl0-^ M, while arεenic and cadmium εhow extremely toxic. EXAMPLE 7 In vitro toxicity testε on kidney, lung and bone- marrow primary cultures.
Kidney and lung cellε were recovered as deεcribed by Campbell, J. A. et al. ("Siεter cromatid exchange analysis of mice following in vitro exposure to vinyl carbonate", In vitro Cell. Dev . Biol. 22: 443:448,
1986) .
Briefly, kidneys were removed from the same animals subjected to liver perfuεion, waεhed 3 timeε in PBS additioned with antibioticε and minced in 0.5 mm pieceε with a εterile εcalpel. After 1 hour of incubation in trypεin/collagenaεe (lOOU/ml) εolution, the suεpenεion waε centrifuged twice for 5 min. at 50xg, plated in 100 mm Falcon disheε and cultured in McCoy 'ε medium with 20% FCS, 2mM Glutamine and Pen/εtrep.
In order to collect lung cellε, after liver perfusion the chest cavity was opened after liver perfuεion to acceεε the lungε. The trachea waε cut with a scalpel and a 22-gauge catheter waε inserted into the trachea to perfuse the lungs with trypsin/collagenase εolution for 5 min. in order to help the disaggregation of this tissue. The cells were then trypsinized, εeeded in 24 wells and left to grow until confluence in McCoy's medium with 20% FCS, 2mM Glutamine and antibiotics. In order to prepare bone marrow primary cultures, bone marrow cells were flushexd from the cavity of femurs and tibias with a εyringe containing the culture medium. Cellε were plated in 12 well plateε with McCoy' ε medium with 20% FCS, 2mM Glutamine and antibioticε, and left to grow until the εtromal cellε reached confluence.
To evaluate the toxic effect of the compoundε, the same procedure waε followed aε in the above examples 5 and 6.
Results are reported in the Table.
Table (A) Determination of hGH (pg/10" cells) release and primary transgenic cultures viability after 5-hour treatment
hGH re lease Viabi •lty ,
Compounds Primary lines 10-5M 5x10" -5M 10"4M 5xl0_4M 10_5M 5x10" °M 10_4M 5xlO_4M
CaCl2 hepatocytes nd nd nd nd + + + +
RbCl nd nd nd nd + + + +
CrCl3 / nd nd nd / + + +
CuS04 / nd 80 66 / + + +
K2Cr207 nd 65 94 65 + /- + /- - -
CH3HgCl nd nd nd / + /- +/- - /
CdCl2 309 452 57 14 + /- +/- - CJ1
NaAs02 100 224 nd / + +/- - /
CaCl2 E bryonic / nd nd nd / + + +
RbCl f ibroblast / nd nd nd / + + +
CrCl3 / nd nd nd / + + +
CuS04 / nd 6 12 / + + +
K2Cr207 9 nd nd nd + /- + /- - -
CH3HgCl / nd nd nd / + /- - /
CdCl2 250 85 45 nd + /- +/- - -
NaAs02 nd 113 19 nd + + /- + /- /
cont inues
CaCl2 Kidney / nd nd nd / + + + RbCl cells / 57 nd nd / + + + CrCl 3 / nd 15 nd / + + +/ CuS04 / nd nd nd / + +/- +/ KnCr n J-j nd nd nd / +/- +/- +/- /
CH3HgCl 10 nd nd / +/- +/- +/- /
CdCl2 nd nd nd / +/- - / NaAsO 22 17 28 / + +/- - /
CaCl2 Lungs / nd 127 202 / + + +
RbCl cells / 28 191 71 / + + +
CrCl3 / 92 122 166 / + + + CTl
CuS04 / nd nd 184 / +/- +/- +/
K2Cr207 nd nd nd / +/- - /
CH3HgCl 27 nd nd / - /
CdCl2 nd 31 11 / +/- - /
NaAsOo nd 37 249 / +/- + / ■ - /
hGH levels in untreated cells medium (controls) were not measurable after 5-24-hour incubation . nd = undetectable; / = not determined; + = with 100% viability; with 30-70% viability; - = 100% dead
(R) Determination of hGH (pg/10^ cells) release and primary transgenic coltures after 24- hour treatment.
hGH release Vitality λ
Compounds Primary lines 10_5M 5x10" "5M 10~4M 5xlO~4M 10_5M 5x10" "^M 10_4M 5xl0-4M
CaCl2 hepatocytes nd nd nd nd + + + +
RbCl nd nd nd nd + + + +
CrCl3 / 36 20 nd / + + -
CuS04 / 12 61 100 / + + + /-
K2Cr2°7 nd nd nd nd - - - -
CH3HgCl nd 63 103 / + /- - - /
CdCl2 nd nd 17 21 + /- + /- - -
NaAs02 270 19 5 / + + /- - /
CaCl2 Embryonic / nd nd nd / + + +
RbCl f ibroblast / nd nd nd / + + +
Figure imgf000019_0001
continues
CaCl2 Kidney / nd nd nd / + + +
RbCl cells / nd nd nd / + + +
Figure imgf000020_0001
CaCl2 Lungε / nd nd nd / + + + /-
RbCl cells / 20 110 114 / + + + /-
Figure imgf000020_0002
CaCl2 Bone marrow / nd 51 nd / + + + /-
RbCl cells / nd 20 128 / + + + /-
Figure imgf000020_0003
hGH levels in untreated cells medium (controls) were not measurable after 24-hour incubation. nd = undetectable; / = not determined; + = with 100% viability; with 30-70% viability; - = 100% dead

Claims

1. A non-human tran╬╡genic animal which comprises cell╬╡ containing a construct of a stress-╬╡en╬╡itive regulatory sequence linked to a reporter-gene sequence.
2. A non-human tran╬╡genic animal according to claim 1, wherein ╬╡aid regulatory ╬╡equence i╬╡ the heat shock protein (hsp) promoter.
3. A non-human transgenic animal according to claim 2, wherein said ╬╡equence is hsp70 gene promoter.
4. A non-human transgenic animal according to claims 1-3, wherein said reporter gene is the growth hormone (GH) gene.
5. A non-human transgenic animal according to any of the previous claims, which is a mammal.
6. A non-human transgenic animal according to claim 5, which is a rodent.
7. A non-human transgenic animal according to claim 6, which i╬╡ a mouse.
8. A primary cell culture obtained from the transgenic animals of claims 1-7, wherein cells bear a construct of a stress-sensitive regulatory sequence linked to a reporter-gene sequence.
9. A primary cell culture according to claim 8, which is a fibrobla╬╡t, hepatocyte, kidney, lung and bone marrow-cell culture.
10. A method for the study of chemical, physical and biological toxic agents which comprises: a) exposing the transgenic animal of claims 1-7 to the toxic agent; b) determining the effect through measurement of the reporter-gene expre╬╡╬╡ion.
11. A method according to claim 10, wherein the ╬╡ame animal i╬╡ u╬╡ed for repeated te╬╡t╬╡ with the ╬╡ame or different toxic agent.
12. A method according to claim╬╡ 10-11, for the ╬╡tudy of toxicity kinetics of one or more toxic agents.
13. A method according to claims 10-12, for the study of heat stress.
14. A method according to claims 10-12, for the study of metal toxicity.
15. A method according to claim 14 for the study of toxicity of metals selected from the group consisting of Rb, Cu, Hg, As and C .
16. A method for the toxicity study of chemical, physical and biological agents, which comprises: a) preparing a primary culture from the tran╬╡genic animal of claims 1-7, in which the cultured cells bear a construct of a stre╬╡╬╡- ╬╡ensitive regulatory sequence linked to a reporter-gene sequence; b) exposing the primary culture to the toxic agent; c) determining the effect through the expression of the reporter gene in the culture medium.
17. A method according to claim 16, wherein fibrobla╬╡t and hepatocyte primary culture╬╡ are u╬╡ed.
18. A method according to claim╬╡ 16-17 for the ╬╡tudy of metal toxicity.
19. A method according to claim 18, wherein metal╬╡ are ╬╡elected from the group con╬╡i╬╡ting of Rb, Cr, Cu, Hg,
A╬╡ , and Cd .
20. The u╬╡e of the tran╬╡genic animal of claim 1 for in vivo toxicity ╬╡tudies.
21. The u╬╡e of a tran╬╡genic animal according to claim 19, wherein ╬╡aid animal i╬╡ a mou╬╡e.
22. The u╬╡e of primary culture╬╡ of cell╬╡ from the tran╬╡genic animal of claim 1, for in vitro toxicity studies .
PCT/IT1998/000231 1997-08-28 1998-08-11 Transgenic animals for the study of biological, physical and chemical toxic agents WO1999011772A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000508783A JP2001514848A (en) 1997-08-28 1998-08-11 Transgenic animals for studying biological, physical and chemical virulence factors
CA002302220A CA2302220A1 (en) 1997-08-28 1998-08-11 Transgenic animals for the study of biological, physical and chemical toxic agents
AU86469/98A AU8646998A (en) 1997-08-28 1998-08-11 Transgenic animals for the study of biological, physical and chemical toxic agents
EP98937782A EP1029037A1 (en) 1997-08-28 1998-08-11 Transgenic animals bearing stress sensitive regulatory sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI971972 IT1294450B1 (en) 1997-08-28 1997-08-28 TRANSGENIC ANIMALS FOR THE STUDY OF PHYSICAL OR BIOLOGICAL CHEMICAL TOXIC AGENTS
ITMI97A001972 1997-08-28

Publications (1)

Publication Number Publication Date
WO1999011772A1 true WO1999011772A1 (en) 1999-03-11

Family

ID=11377792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1998/000231 WO1999011772A1 (en) 1997-08-28 1998-08-11 Transgenic animals for the study of biological, physical and chemical toxic agents

Country Status (6)

Country Link
EP (1) EP1029037A1 (en)
JP (1) JP2001514848A (en)
AU (1) AU8646998A (en)
CA (1) CA2302220A1 (en)
IT (1) IT1294450B1 (en)
WO (1) WO1999011772A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036106A2 (en) * 1998-12-17 2000-06-22 Xenogen Corporation Non-invasive evaluation of physiological response in a mammal
WO2004016777A2 (en) * 2002-08-14 2004-02-26 Consorzio Interuniversitario Per Le Biotecnologie C/O Università Degli Studi Di Trieste Genetically modified non-human mammal cells, procedure for their production and use in toxicity tests
DE102007035238A1 (en) 2007-07-27 2009-01-29 Christian-Albrechts-Universität Zu Kiel Biological effect monitoring by transgenic Hydra

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263908A1 (en) * 1986-10-15 1988-04-20 Battelle Memorial Institute Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo
EP0336523A1 (en) * 1988-04-08 1989-10-11 IntraCel Corporation Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
CA2088379A1 (en) * 1993-01-29 1994-07-30 University Of British Columbia Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology
WO1998028971A2 (en) * 1997-01-03 1998-07-09 University Technology Corporation Transgenic animals for in vivo visualization of beta-amyloid toxicity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263908A1 (en) * 1986-10-15 1988-04-20 Battelle Memorial Institute Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo
EP0336523A1 (en) * 1988-04-08 1989-10-11 IntraCel Corporation Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
CA2088379A1 (en) * 1993-01-29 1994-07-30 University Of British Columbia Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology
WO1998028971A2 (en) * 1997-01-03 1998-07-09 University Technology Corporation Transgenic animals for in vivo visualization of beta-amyloid toxicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUVEN, K. ET AL.: "Evaluation of a stress-inducible transgenic nematode strain for rapid aquatic toxicity testing", AQUATIC TOXICOLOGY, vol. 29, no. 1-2, June 1994 (1994-06-01), pages 119 - 137, XP002089378 *
SACCO, M.G. ET AL.: "A transgenic mouse model for the detection of cellular stress induced by toxic inorganic compounds", NATURE BIOTECHNOLOGY., vol. 15, no. 13, December 1997 (1997-12-01), UBLISHING US, pages 1392 - 1397, XP002089379 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036106A2 (en) * 1998-12-17 2000-06-22 Xenogen Corporation Non-invasive evaluation of physiological response in a mammal
WO2000036106A3 (en) * 1998-12-17 2000-11-02 Xenogen Corp Non-invasive evaluation of physiological response in a mammal
US7449615B2 (en) 1998-12-17 2008-11-11 Xenogen Corporation Non-invasive evaluation of physiological response in a transgenic mouse
WO2004016777A2 (en) * 2002-08-14 2004-02-26 Consorzio Interuniversitario Per Le Biotecnologie C/O Università Degli Studi Di Trieste Genetically modified non-human mammal cells, procedure for their production and use in toxicity tests
WO2004016777A3 (en) * 2002-08-14 2004-03-25 Consorzio Interuniversitario P Genetically modified non-human mammal cells, procedure for their production and use in toxicity tests
DE102007035238A1 (en) 2007-07-27 2009-01-29 Christian-Albrechts-Universität Zu Kiel Biological effect monitoring by transgenic Hydra

Also Published As

Publication number Publication date
EP1029037A1 (en) 2000-08-23
AU8646998A (en) 1999-03-22
ITMI971972A1 (en) 1999-02-28
CA2302220A1 (en) 1999-03-11
JP2001514848A (en) 2001-09-18
IT1294450B1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
AU774183B2 (en) Non-invasive evaluation of physiological response in a mammal
Chen et al. Generation of a transgenic mouse model with chondrocyte‐specific and tamoxifen‐inducible expression of Cre recombinase
Larochelle et al. Engraftment of immune-deficient mice with primitive hematopoietic cells from β-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols
WO2011002988A1 (en) Genetically modified rat models for severe combined immunodeficiency (scid)
US11051496B2 (en) Urokinase-type plasminogen activator transgenic mouse
Sacco et al. A transgenic mouse model for the detection of cellular stress induced by toxic inorganic compounds
US8487087B2 (en) Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
US20060130168A1 (en) Transgenic non-human mammals as models for human pathologies of stem cell origin
WO1999011772A1 (en) Transgenic animals for the study of biological, physical and chemical toxic agents
Pagès et al. Study of MAPK signaling using knockout mice
WO2001056375A1 (en) Tob gene-defective knockout nonhuman mammal
KR100984643B1 (en) Zebrafish introduced estrogen responsive reporter gene and method for screening estrogenic chemicals using the same
JPWO2005115133A1 (en) Gene transfer method to in vivo spermatogenic cells
Hosur et al. Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils
EP2695515B1 (en) Epo knockout gfp anemic mouse
EP1840570A1 (en) Tumor models employing green fluorescent protein
US20070204353A1 (en) Transgenic animals and methods of monitoring hedgehog responding cells
US20060242726A1 (en) Methods and vectors for making knockout animals
US6677501B2 (en) P2X7 receptor-deficient mice and uses thereof
Ladiges et al. Transgenic animals in toxicology
JP2006522598A (en) Methods for determining xenograft response
WO2005116070A9 (en) Reporter system for detecting signal pathway activation in multiple cell types

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2302220

Country of ref document: CA

Ref country code: CA

Ref document number: 2302220

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998937782

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998937782

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09486660

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998937782

Country of ref document: EP